Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A new perspective on antiangiogenic antibody drug resistance: Biomarkers, mechanisms, and strategies in malignancies

1 Sept 2024

Abstract excerpt

Drug resistance of malignant tumor leads to disease progression be the bottleneck in clinical treatment. Antiangiogenic therapy, which aims to "starve" the tumor by inhibiting angiogenesis, is one of the key strategies in clinical oncology treatments. Recently, dozens of investigational antibody drugs and biosimilars targeting angiogenesis have obtained regulatory approval for the treatment of various...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis and VEGF in Cancer
Share to Cancer Mechanisms and Therapy
Share to Hepatocellular Carcinoma Treatment and Prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39245913
DOI: 10.1002/ddr.22257

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A new perspective on antiangiogenic antibody drug resistance: Biomarkers, mechanisms, and strategies in malignanciesPMID 39245913Read ↗

Anti-angiogenesis therapy in cancer: current challenges and future perspectives.Semantic proximity Read ↗

Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway.Semantic proximity Read ↗

Tumor angiogenesis: causes, consequences, challenges and opportunitiesSemantic proximity Read ↗

Tumor Microenvironment: A Complex Landscape of Cancer Development and Drug ResistanceSemantic proximity Read ↗

The Evolution of Acquired Resistance to BRAFV600E kinase inhibitor Is Sustained by IGF1-Driven Tumor Vascular RemodelingSemantic proximity Read ↗

Current Status of Angiogenesis Inhibitors as Second-Line Treatment for Unresectable Colorectal CancerSemantic proximity Read ↗

Endothelial cell malignancies: new insights from the laboratory and clinicSemantic proximity Read ↗

What "helps" tumors evade vascular targeting treatment?Semantic proximity Read ↗

Tumor angiogenesis: molecular pathology, therapeutic targeting, and imaging.Semantic proximity Read ↗

Acquired resistance to BRAF inhibitory treatments requires tumor tissue remodeling and reveals targetable vulnerabilities in colorectal cancerSemantic proximity Read ↗

Synchronizing Cancer Research Worldwide, a Way of Overcoming Resistance to Anti-angiogenic DrugsSemantic proximity Read ↗

Resistance to EGF-R (erbB-1) and VEGF-R modulating agents.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.